title: [Modern risk assessment and stroke prevention in atrial fibrillation].
abstract: Stroke prophylaxis in patients with non-valvular atrial fibrillation is becoming an increasingly dynamic field. The new guidelines from the European Society of Cardiology (ESC) recommend a stroke- and bleeding risk-assessment in patients with non-valvular atrial fibrillation using the CHA2DS2VASc and the HAS-BLED scores, respectively. Furthermore, new drugs for stroke prophylaxis such as dabigatran, rivaroxaban and apixaban are undergoing approval in Europe and will undoubtedly challenge the well-established vitamin K antagonists. Hence, stroke prophylaxis is likely to become a much more individualized treatment in the future. This review should help to critically weigh the pros and the cons of the new therapeutic options.
authors.affiliation: Klinik für Hämatologie, Universitätsspital Zürich. bernhard.gerber@usz.ch
authors.forename: B
authors.initials: B
authors.lastname: Gerber
authors.forename: O
authors.initials: O
authors.lastname: Senn
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications* / Q000175:diagnosis; D005060:Europe; D005260:Female; D006801:Humans; D008297:Male; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D020521:Stroke / Q000209:etiology* / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants